A phase I dose escalation and cohort expansion study of lirilumab (anti-KIR; BMS-986015) in combination with nivolumab (anti-PD-1; BMS-936558, ONO-4538) in advanced solid tumors Meeting Abstract
| Authors: | Segal, N. H.; Hodi, F. S.; Sanborn, R. E.; Gajewski, T.; Wolchok, J. D.; Urba, W. J.; Fox, B. A.; Topallan, S. L.; Pardoll, D. M.; Kollia, G.; McDonald, D.; Kim, S. Y.; Sharfman, W. H. |
| Abstract Title: | A phase I dose escalation and cohort expansion study of lirilumab (anti-KIR; BMS-986015) in combination with nivolumab (anti-PD-1; BMS-936558, ONO-4538) in advanced solid tumors |
| Meeting Title: | 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 32 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2014 May 30-Jun 3 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2014-05-20 |
| Language: | English |
| ACCESSION: | WOS:000358613202053 |
| PROVIDER: | wos |
| DOI: | 10.1200/jco.2014.32.15_suppl.TPS3115 |
| Notes: | Meeting Abstract: TPS3115 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work